Gossamer Bio is trading at $10.08, up +5.22%, with biotech sector strength potentially supporting shares; no clearly reported company-specific announcement explains the October 21 move. - The latest company press-release listing surfaced in search was dated October 13. - The supplied sector context reports XBI up 2.10%, amid sector M&A and clinical-trial optimism. - Shares closed at $9.58 after gaining 13.64% on October 20, according to a market report.